ICU Stock Forecast: Seastar Medical Holding Corp. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$0.91
−13.32% on the day

The median 12-month analyst price target for Seastar Medical Holding Corp. is $10. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 26 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$5.0M
Ticker Nerd rank
26/ 100
Median analyst target
$10
Analysts covering
1
Revenue$615K+82.0% y/y
Operating income−$3.8M
Net income−$3.7M
Free cash flow−$3.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+8.6%
1M
−70.2%
YTD
−62.1%
1Y
−70.6%
From 52W high
−82.1%
From 52W low
+16.5%
$0.78
$5.08
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Seastar Medical Holding Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
26/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
69
Growth
45
Revisions
42
Volatility
28
Issuance
26
Quality
25
Value
17
Momentum
17

Accruals (69): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (17): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

ICU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ICU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26ICUHigh $12Median $10Low $8

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1
Buy
0
Hold
0
Sell
$8
Low
$10
Median
$12
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
14 May 2026Maxim GroupMaintainsBuy$6.00 → $8.00
20 Apr 2023Maxim GroupInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for ICU.

Market Radar

This page is one stock. Monday covers all of them.

ICU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

ICU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Seastar Medical Holding Corp. returned −70.6% against +6.9% for the S&P 500, dividends included.

ICU vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150Jan 26Apr 26Jul 26Oct 26ICUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ICU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
2.3×

Cheaper than 44% of US stocks

Price / book
0.3×

Cheaper than 90% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
91.2%

Higher than 97% of US stocks

Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−246.1%

Higher than 6% of US stocks

Return on assets
−89.9%

Higher than 3% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Seastar Medical Holding Corp. has a market value of $5.0M and an enterprise value of $981K.

  • Revenue in the twelve months to 30 June 2026: $1.7M. The latest quarter grew 82.0% year on year.

  • Net income over the same four quarters: −$13.6M, a −795.5% net margin.

  • Diluted earnings per share, trailing twelve months: −$3.91.

  • Free cash flow in the twelve months to 30 June 2026: −$13.7M.

  • Shares outstanding: 4.3M.

  • Seastar Medical Holding Corp. employs 17 people — $101K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 21 Nov 2026

Data provided by Twelve Data

Peers

ICU and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ICUSeastar Medical Holding Corp.$5.0M26
NIKINiki Biosolutions, Inc.$4.9M9
SNGXSoligenix, Inc.$5.1M26
CNSPCNS Pharmaceuticals, Inc.$5.2M15
CDIOCardio Diagnostics Holdings, Inc.$4.7M20
VIVSVivoSim Labs, Inc.$5.3M25
PULMPulmatrix, Inc.$4.6M47

Take a look at ICU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Seastar Medical Holding Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about ICU

What is the ICU stock price forecast for 2026-2027?

The median 12-month analyst price target for Seastar Medical Holding Corp. is $10, with estimates ranging from $8 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ICU stock a buy right now?

Of the 1 analyst covering Seastar Medical Holding Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Seastar Medical Holding Corp. 26 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ICU?

As at 21 Nov 2026, Seastar Medical Holding Corp. ranks 26 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (69 of 100).

Will ICU stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $10, and Ticker Nerd's factor model ranks Seastar Medical Holding Corp. 26 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ICU stock forecast for 2030?

No analyst covering Seastar Medical Holding Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ICU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $8 to $12 over the next 12 months.

How has ICU stock performed over the past year?

Seastar Medical Holding Corp. returned -70.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Seastar Medical Holding Corp. do?

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation.

Company

About Seastar Medical Holding Corp.

SeaStar Medical Holding Corporation is a commercial-stage medical device company focused on therapies for critically ill patients facing organ failure and severe inflammatory conditions. SeaStar Medical develops and commercializes extracorporeal treatment systems centered on its Selective Cytopheretic Device platform, which is designed to modulate harmful immune responses and reduce hyperinflammation. The company’s current product portfolio includes QUELIMMUNE, an FDA-approved treatment for pediatric acute kidney injury associated with sepsis or septic condition requiring renal replacement therapy, along with additional SCD-based programs in adult kidney injury and other serious inflammatory indications. Based in Denver, Colorado, SeaStar Medical operates in the medical technology and specialty devices market, addressing unmet needs in hospital intensive care and renal replacement settings.

CEO Mr. Eric Schlorff · 17 employees · United States · https://seastarmedical.com